Eyetech Pharmaceuticals


Eyetech Pharmaceuticals
New York, NY
Founded: 2000

Why It's Fierce: Eyetech is the exception that proves the rule academics cannot run a company. New York University medical school professor David Guyer and Harvard medical school associate professor Anthony Adamis signed a $745 million collaboration with Pfizer in December to develop Macugen, an anti-vascular endothelial growth factor for age-related macular degeneration and diabetic macular edema. What will Eyetech do for an encore?

What to look for in 2003: The company expects to file a new drug application for Macugen in the coming months.

Eyetech Pharmaceuticals

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.